Helicobacter pylori cytotoxin-associated gene-A antibodies do not predict complications or death in type 2 diabetes: The Fremantle Diabetes Study

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 321-326

  Schimke, Katrin ^a   Chubb, Stephen A P ^b   Davis, Wendy A ^a   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

Cardiovascular disease; Cytotoxin associated gene A (CagA) antigen; Diabetic nephropathy; Helicobacter pylori; Mortality; Type 2diabetes

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CAGA PROTEIN, HELICOBACTER PYLORI;

AGED; ARTICLE; AUSTRALIA; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; INCIDENCE; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME;

AGED; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; AUSTRALIA; BACTERIAL PROTEINS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

MLCS; MLOWN;

EID: 79952111193     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.05.021     Document Type: Article

References (30)

1. Crabtree, J.E., Kersulyte, D., Li, S.D., Lindley, I.J., Berg, D.E., Modulation of Helicobacter pylori induced interleukin-8 synthesis in gastric epithelial cells mediated by cag PAI encoded VirD4 homologue. J Clin Pathol 52 (1999), 653–657.
2. Ameriso, S.F., Fridman, E.A., Leiguarda, R.C., Detection of Helicobacterpylori in human carotid arteries. Stroke 32 (2001), 385–391.
3. Lindsberg, P.J., Grau, A.J., Inflammation and infections as risk factors for ischemic stroke. Stroke 34 (2003), 2518–2532.
4. Zhang, S., Guo, Y., Ma, Y., Teng, Y., Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chin Med J (Engl) 121 (2008), 946–951.
5. Bunch, T.J., Day, J.D., AndersonJL, et al. Frequency of Helicobacter pylori seropositivity and C-reactive protein increase in atrial fibrillation in patients undergoing coronary angiography. Am J Cardiol 101 (2008), 848–851.
6. Lunetta, M., Fazio, G., Avena, V., et al. Helicobacter pylori and atrial fibrillation: absence of correlations. J Cardiovasc Med (Hagerstown) 10 (2009), 4–5.
7. Badran, H.M., Mahfouz, M.E., Cytotoxin-associated gene-A bearing strains of Helicobacter pylori and atrial fibrillation due to ischemic origin: is there a link?. Eur J Cardiovasc Prev Rehabil 14 (2007), 518–520.
8. Dore, M.P., Bilotta, M., Malaty, H.M., et al. Diabetes mellitus and Helicobacter pylori infection. Nutrition 16 (2000), 407–410.
9. Ongey, M., Brenner, H., Thefeld, W., Rothenbacher, D., Helicobacter pylori and hepatitis A virus infections and the cardiovascular risk profile in patients with diabetes mellitus: results of a population-based study. Eur J Cardiovasc Prev Rehabil 11 (2004), 471–476.
10. Schimke, K., Chubb, S.A., Davis, W.A., Phillips, P., Davis, T.M., Antiplatelet therapy, Helicobacter pylori infection and complicated peptic ulcer disease in diabetes: the Fremantle Diabetes Study. Diabet Med 26 (2009), 70–75.
11. Pietroiusti, A., Giuliano, M., Magrini, A., Bergamaschi, A., Galante, A., Cytotoxin-associated gene A strains of Helicobacter pylori represent a risk factor for the development of microalbuminuria in type 2 diabetes. Diabetes Care 29 (2006), 1399–1401.
12. Franceschi, F., Sepulveda, A.R., Gasbarrini, A., et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Heli-cobacter pylori infection and atherosclerosis. Circulation 106 (2002), 430–434.
13. Yudkin, J.S., Forrest, R.D., Jackson, C.A., Microalbuminuria as predictor of vascular disease in non-diabetic subjects, Islington Diabetes Survey. Lancet 2 (1988), 530–533.
14. Stehouwer, C.D., Nauta, J.J., Zeldenrust, G.C., et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340 (1992), 319–323.
15. Davis, T.M., Zimmet, P., Davis, W.A., et al. Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 17 (2000), 667–674.
16. Davis, W.A., Norman, P.E., Bruce, D.G., Davis, T.M., Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 49 (2006), 2634–2641.
17. Levey, A.S., Bosch, J.P., Lewis, J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Inter Med 130 (1999), 461–470.
18. Feldman, E.L., Stevens, M.J., Thomas, P.K., et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17 (1994), 1281–1289.
19. Laheij, R.J., Straatman, H., Jansen, J.B., Verbeek AL Evaluation of commercially available Helicobacter pylori serology kits: a review. J Clin Microbiol 36 (1998), 2803–2809.
20. Basso, D., Stefani, A., Brigato, L., et al. Serum antibodies anti-H. pylori and anti-CagA: a comparison between four different assays. J Clin Lab Anal 13 (1999), 194–198.
21. Holman, C.D., Bass, A.J., Rouse, I.L., Hobbs, M.S., Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23 (1999), 453–459.
22. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998:352:837-53.
23. Anastasios, R., Goritsas, C., Papamihail, C., et al. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 13 (2002), 376–379.
24. Sugimoto, M., Yamaoka, Y., Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz) 57 (2009), 45–56.
25. Markus, H.S., Risley, P., Mendall, M.A., Steinmetz, H., Sitzer, M., Helicobacter pylori infection, the cytotoxin gene A strain, and carotid artery intima-media thickness. J Cardiovasc Risk 9 (2002), 1–6.
26. Andrew, P., Montenero, A.S., Is Helicobacter pylori a cause of atrial fibrillation?. Future Cardiol 2 (2006), 429–439.
27. Platonov, P., Ekesbo, R., Hansson, A., et al. Permanent atrial fibrillation in patients without structural heart disease is not associated with signs of infection by Chlamydia pneumoniae and Helicobacter pylori. Acta Cardiol 63 (2008), 479–484.
28. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol 2001:52:3-31.
29. Stone, A.F., Mendall, M.A., Kaski, J.C., et al. Effect of treatment for Chlamydia pneu-moniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106 (2002), 1219–1223.
30. Yusuf, S., Hawken, S., Ounpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.